Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Brooks Life Science Systems Announces New Applications for Celigo® Imaging Cytometer

Published: Monday, January 14, 2013
Last Updated: Monday, January 14, 2013
Bookmark and Share
Company develops new and improved applications for use in cell line generation and oncology research.

Brooks Life Science Systems has announced that its ongoing investment and development of the Celigo® Imaging Cytometer is bringing new capabilities to academic research, biopharmaceutical drug development and high-throughput and high-content screening.

Celigo is a multi-application cell imaging cytometer able to perform high-content and high-throughput fluorescence and brightfield cellular imaging and analysis with minimal sample manipulation.

Following the acquisition of the Celigo Imaging Cytometer product earlier this year, Brooks Life Science Systems has developed a number of new and improved applications for use in cell line generation and oncology research.

New applications include:
• Tumor growth analysis in drug screening: brightfield and fluorescence acquisition of tumorspheres with fluorescence & morphologic measurements
• Single colony verification: enumeration of colonies within a well for identification of single clones
• Cell migration measurement: assessment of wound healing via typical scratch assays
• Faster automated measurement of cell counting & confluency
• Improved reproducibility and reliability of embryoid body segmentation

Dr Suzanne Eccles, Reader in Tumor Biology at the Institute of Cancer Research, Sutton commented, “Celigo has been essential to our work validating 3D models of tumor growth, invasion and angiogenesis. We now have robust, high-throughput growth assays, with results for 96-well plates in minutes compared with standard automated microscopy-based image analysis, and we have been able to develop novel quantitative, measurements of tumor invasion.

“By using the Celigo in our drug discovery research we have more clinically relevant models for drug evaluation which are contributing to a reduction in the amount of in vivo testing being performed.”

Clint Haris, Senior Vice President, General Manager, Brooks Life Science Systems added, “Cell analysis is a fast moving field that requires versatile instrumentation capable of meeting challenging demands. The development of these new applications is ensuring that Celigo continues to meet the needs of our customers and highlights our commitment to supporting the field of cell analysis.”

Brooks Celigo is designed for the rapid image capture and processing of cells with minimum plate movements and sample disturbance.

Proven with both adherent and non-adherent cell types, its high resolution image acquisition coupled with uniform, high contrast and even illumination allows identification of “every cell in every well”.

Compatibility with SBS multi-well plates along with T25 and T75 culture flasks, a simplified workflow for all assays and enhanced software capabilities, enables the Celigo to be used in a broad range of applications.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!